Carlos Galaviz-Hernandez1, Eliakym Arámbula-Meraz2, Diana Medina-Bastidas2, Martha Sosa-Macías3, Blanca P Lazalde-Ramos4, Margarita Ortega-Chávez3, Lorena Hernandez-García5. 1. Instituto Politécnico Nacional, CIIDIR-Durango, 34220 Durango, Mexico. Electronic address: carlosgalavizhernandez55@gmail.com. 2. Facultad de Ciencias Químico-Biológicas, Universidad Autónoma de Sinaloa, 80040 Culiacán Rosales, Sinaloa, Mexico. 3. Instituto Politécnico Nacional, CIIDIR-Durango, 34220 Durango, Mexico. 4. Unidad Académica de Ciencias Químicas, Universidad Autónoma de Zacatecas, 98000 Zacatecas, Mexico. 5. Hospital General de Durango, Secretaría de Salud Durango, 34000 Durango, Mexico.
Abstract
OBJECTIVE: To evaluate whether the maternal, paternal or the combined maternal/paternal contribution of SNP rs5370 of the EDN1 gene is associated with preeclampsia and drove its expression in placenta. STUDY DESIGN: This case-control study included 61 preeclamptic patients and their partners and 49 healthy pregnant women and their partners. The population was sub-divided into three groups: women-only, men-only and combined (women/men). The analysis included genotyping of rs5370 in mothers and fathers and evaluating the expression profile of the EDN1 gene in placenta. Comparisons of categorical variables were performed using chi-square and/or Fisher's exact tests. The intergroup comparisons were analysed with the Mann-Whitney U test. The association between the polymorphism and the disease was evaluated through multivariate regression analysis. Spearman's correlation was performed to test the relationship between pre-gestational history and clinical features of the affected patients with EDN1 gene expression. RESULTS: The analysis of paternal risk factors associated with preeclampsia revealed no differences between groups. A negative association between SNP rs5370 and preeclampsia was found in men group (OR 0.42; CI 95% 0.18-0.94, p=0.034) but not in women or combined groups. The adjustment for paternal protective factors increased the observed negative association, and the opposite was observed in the presence of paternal risk factors. The expression of the EDN1 gene in the placenta was significantly higher in the group of cases and was not associated with the rs5370 polymorphism. CONCLUSION: The paternal rs5370 polymorphism decreases the risk for preeclampsia and is not associated with placental expression of the EDN1 gene.
OBJECTIVE: To evaluate whether the maternal, paternal or the combined maternal/paternal contribution of SNP rs5370 of the EDN1 gene is associated with preeclampsia and drove its expression in placenta. STUDY DESIGN: This case-control study included 61 preeclamptic patients and their partners and 49 healthy pregnant women and their partners. The population was sub-divided into three groups: women-only, men-only and combined (women/men). The analysis included genotyping of rs5370 in mothers and fathers and evaluating the expression profile of the EDN1 gene in placenta. Comparisons of categorical variables were performed using chi-square and/or Fisher's exact tests. The intergroup comparisons were analysed with the Mann-Whitney U test. The association between the polymorphism and the disease was evaluated through multivariate regression analysis. Spearman's correlation was performed to test the relationship between pre-gestational history and clinical features of the affected patients with EDN1 gene expression. RESULTS: The analysis of paternal risk factors associated with preeclampsia revealed no differences between groups. A negative association between SNP rs5370 and preeclampsia was found in men group (OR 0.42; CI 95% 0.18-0.94, p=0.034) but not in women or combined groups. The adjustment for paternal protective factors increased the observed negative association, and the opposite was observed in the presence of paternal risk factors. The expression of the EDN1 gene in the placenta was significantly higher in the group of cases and was not associated with the rs5370 polymorphism. CONCLUSION: The paternal rs5370 polymorphism decreases the risk for preeclampsia and is not associated with placental expression of the EDN1 gene.
Authors: Jutta Pretscher; Matthias Ruebner; Arif B Ekici; Melanie Rödl; Hanna Huebner; Judith Schwitulla; Adriana Titzmann; Charlotte Hartwig; Matthias W Beckmann; Peter A Fasching; Michael O Schneider; Eva Schwenke Journal: Arch Gynecol Obstet Date: 2020-09-30 Impact factor: 2.344
Authors: Maria A Nieves-Colón; Keyla M Badillo Rivera; Karla Sandoval; Vanessa Villanueva Dávalos; Luis E Enriquez Lencinas; Javier Mendoza-Revilla; Kaustubh Adhikari; Ram González-Buenfil; Jessica W Chen; Elisa T Zhang; Alexandra Sockell; Patricia Ortiz-Tello; Gloria Malena Hurtado; Ramiro Condori Salas; Ricardo Cebrecos; José C Manzaneda Choque; Franz P Manzaneda Choque; Germán P Yábar Pilco; Erin Rawls; Celeste Eng; Scott Huntsman; Esteban Burchard; Andrés Ruiz-Linares; Rolando González-José; Gabriel Bedoya; Francisco Rothhammer; Maria Cátira Bortolini; Giovanni Poletti; Carla Gallo; Carlos D Bustamante; Julie C Baker; Christopher R Gignoux; Genevieve L Wojcik; Andrés Moreno-Estrada Journal: Am J Hum Genet Date: 2022-05-18 Impact factor: 11.043